Showing results (881-890 of 1,566) with videos related to
Sort By:
Pageof 157
Asia-Pacific Journal of Clinical Oncology|November 14, 2019
Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single instituteKeisuke Kodama, Kenzo Sonoda, Masako Kijima, et al.Asia-Pacific Journal of Clinical Oncology|November 28, 2019
S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in TaiwanChun-Liang Lai, Yu-Fen Wei, Te-Chun Hsia, et al.Asia-Pacific Journal of Clinical Oncology|February 13, 2019
What contributes to resilience in cancer patients? A principal component analysis of the Connor-Davidson Resilience ScaleWei Son Tan, Lisa Beatty, Emma Kemp, et al.Asia-Pacific Journal of Clinical Oncology|December 2, 2017
Visibility of an iron-containing fiducial marker in magnetic resonance imaging for high-precision external beam prostate radiotherapyOsamu Tanaka, Hisao Komeda, Shigeki Hirose, et al.Asia-Pacific Journal of Clinical Oncology|January 30, 2019
Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort studyYue Yu, Jianming Ying, Wen Zhang, et al.Asia-Pacific Journal of Clinical Oncology|January 30, 2019
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lungJui-Feng Hsu, Yen-Lung Lee, Hsu-Liang Chang, et al.Asia-Pacific Journal of Clinical Oncology|February 1, 2019
Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter studyFrancis J Ha, Lavinia Spain, Anthony Dowling, et al.Asia-Pacific Journal of Clinical Oncology|February 8, 2019
Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkersDong Fang, Liqun ZhouAsia-Pacific Journal of Clinical Oncology|March 3, 2018
Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancersCrescens Tiu, Annie Wong, Alan Herschtal, et al.Asia-Pacific Journal of Clinical Oncology|March 3, 2018
A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimensYasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, et al.Pageof 157